CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - Class of Stock [Domain] - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (6,024,480)	$ (9,397,627)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	8,502	0
Loss on extinguishment of notes payable	2,268,373	2,403,193
Decrease in fair value of derivative liabilities	(12,321)	(395,644)
Amortization of discount on notes payable	1,740,150	201,574
Amortization of patents and acquired contracts	831,123	647,738
Net cost of patents sold	215,372	0
Stock-based compensation	596,901	1,861,654
Changes in operating assets and liabilities
Accounts receivable	205,524	(45,965)
Inventories	130,155	15,345
Prepaid expenses and other current assets	(119,008)	(344,953)
Deferred expenses	315,058	0
Deposits and other assets	(10,000)	(16,113)
Accounts payable	(62,805)	426,035
Accrued expenses and other current liabilities	365,091	0
Accrued interest on notes payable	0	73,065
Deferred revenue	596,429	0
Net cash provided by (used in) operating activities	1,044,064	(4,571,698)
Cash flows from investing activities
Restricted cash	0	(3,500,000)
Purchases of property and equipment	0	(45,961)
Issuance of short-term note receivable, related party	0	(3,000,000)
Cash and other assets received in acquisition	0	790,172
Net cash used in investing activities	0	(5,755,789)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	1,835,000	6,487,850
Proceeds from issuance of convertible notes payable, net of issuance costs	0	2,905,128
Proceeds from issuance of notes payable	1,126,900	0
Payments on short-term notes payable, related party	0	(100,000)
Net cash provided by financing activities	2,961,900	9,292,978
Net increase (decrease) in cash and cash equivalents	4,005,964	(1,034,509)
Cash and cash equivalents, beginning of period	1,443,349	1,518,684
Cash and cash equivalents, end of period	5,449,313	484,175
Supplemental disclosures of cash flow information
Cash paid for interest	481,838	83,777
Cash paid for income taxes	0	0
Supplemental disclosures of non-cash investing and financing activities
Accrued guaranteed payments and deferred expenses associated with purchased patent assets	881,501	1,599,977
Conversion of portion of short term note payable, related party, to purchase common stock	100,000	0
Offset of short-term related party notes payable and receivable	0	3,000,000
Transfer of Series A redeemable convertible preferred stock to preferred stock	0	3,392,950
Fair value of convertible notes payable redemption derivative liability	0	385,000
Fair value of common stock warrants	0	348,963
Acquisition of patents	$ 0	$ 2,653,533